Cyclin-dependent kinases (CDK) are attractive targets for drug discovery due to their wide range of cellular functions. CDK11 is an understudied CDK with roles in transcription and splicing, cell cycle regulation, neuronal function, and apoptosis. In this study, we describe a medicinal chemistry campaign to identify a CDK11 inhibitor. Employing a promising but nonselective CDK11-targeting scaffold (JWD-047), extensive structure-guided medicinal chemistry modifications led to the identification of ZNL-05-044. A combination of biochemical evaluations and NanoBRET cellular assays for target engagement guided the SAR towards a 2,4-diaminothiazoles CDK11 probe with significantly improved kinome-wide selectivity over JWD-047. CDK11 inhibition with ZNL-05-044 leads to G2/M cell cycle arrest, consistent with prior work evaluating OTS964, and impacts CDK11-dependent mRNA splicing in cells. Together, ZNL-05-044 serves as a tool compound for further optimization and interrogation of the consequences of CDK11 inhibition.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9477540PMC
http://dx.doi.org/10.1016/j.ejmech.2022.114433DOI Listing

Publication Analysis

Top Keywords

cell cycle
8
medicinal chemistry
8
cdk11 inhibition
8
cdk11
5
synthesis structure-activity
4
structure-activity relationships
4
relationships cyclin-dependent
4
cyclin-dependent kinase
4
kinase inhibitors
4
inhibitors based
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!